Exclusive Summary

• First-in-Class Selectivity: The first selective mTORC2 inhibitor designed to spare mTORC1, offering a significantly wider therapeutic window (>40-fold safety margin) and avoiding common toxicities like hyperglycemia.
• Solution for Drug Resistance: Demonstrates potent efficacy in tough-to-treat resistant models, including EGFR-mutated (T790M) NSCLC and CDK4/6-resistant Breast Cancer, positioning it as a vital next-generation therapy.
• CNS Penetration: Features Blood-Brain Barrier (BBB) penetrability, addressing a critical unmet need for patients with brain metastases in Lung and Breast cancers.
• Strategic Synergy Potential: Novel MOA activating immune responses (biomarker pNRF2) makes it an ideal combination partner for IO therapies (PD-1 inhibitors) and standard-of-care targeted therapies.

Asset Materials

Contact Us for Full Materials